ProMetic Life Sciences Inc. (ProMetic) is a bio-pharmaceutical company offering technologies for large-scale drug purification, drug development, proteomics, clinical diagnostics, and the elimination of pathogens, The Company focuses its activities in two segments: protein technologies and therapeutics. It develops therapeutics to treat blood-related disorders. Its protein technologies are used to remove pathogens from blood and extract and recover proteins from plasma. The Company is developing products to treat anemia, neutropenia, cancer and autoimmune disease/inflammation. ProMetic uses its Affinity Technology, which employs its Mimetic Ligand technology (chemical hooks that selectively recognize and bind to target biomolecules) to facilitate a variety of applications, where a target biomolecule requires purification or removal. Effective May 9, 2014, the Company raised its interest to 60% from 10% by acquiring a 50% interest in NantPro Biosciences LLC.